ORAI1 and breast cancer: While ORAI1 is known to be highly expressed in breast cancers, it was only recently revealed that both the full-length subtype Orai1α and the truncated subtype Orai1β, lacking the N-terminal 63 amino acids, support SOCE in triple-negative MDA–MB–231-derived breast cancer stem cells with similar efficiency, as well as cyclooxygenase (COX) activation and mammosphere formation [115].